Target Name: MBP
NCBI ID: G4155
Review Report on MBP Target / Biomarker Content of Review Report on MBP Target / Biomarker
MBP
Other Name(s): Myelin A1 protein | myelin basic protein | MBP variant 8 | Myelin membrane encephalitogenic protein | myelin membrane encephalitogenic protein | MBP variant 1 | myelin A1 protein | Myelin basic protein | MBP_HUMAN | Myelin basic protein (isoform 1) | Myelin basic protein (isoform 2) | proline-rich proteoglycan 2-like | MBP variant 2 | MP4

MBP: A Promising Drug Target and Biomarker for the Treatment of Multiple Sclerosis

Multiple sclerosis (MS) is a chronic and debilitating autoimmune disorder that affects millions of people worldwide. The immune system attacks the central nervous system, leading to muscle weakness, stiffness, and fatigue. There are currently no FDA-approved treatments for MS, and the disease is often treated with supportive care and lifestyle modifications. However, new research has identified MBP (Myelin A1 protein) as a promising drug target and biomarker for the treatment of MS.

MBP is a transmembrane protein that is synthesized in the central nervous system (CNS) and plays a crucial role in the development and maintenance of the myelin sheath surrounding nerve fibers. In MS, the myelin sheath is damaged, leading to the symptoms associated with the disease. MBP has been shown to be abnormally expressed in the brains of people with MS, and it has been suggested as a potential drug target.

Drug Targeting MBP

MBP is a good candidate for drug targeting due to its unique structure and its involvement in the development and maintenance of the myelin sheath. One of the main reasons for its potential as a drug target is its high expression level in the brain. MBP is expressed in the CNS and is found in the white blood cells that protect the brain, making it an attractive target for drugs that can modulate its levels.

Another reason why MBP is a promising drug target is its role in the regulation of pain perception. MBP has been shown to contribute to pain modulation in the brain, and it is thought to play a key role in the development of neuropathic pain in MS. Therefore, drugs that can modulate MBP levels or its function have the potential to alleviate neuropathic pain in MS.

MBP is also a potential drug target for its role in the regulation of inflammation. MS is associated with an overactive immune system, and the inflammation caused by this system is thought to contribute to the development and progression of the disease. MBP has been shown to be involved in the regulation of inflammation in the brain, and drugs that can modulate its levels or its function may have the potential to slow down the progression of MS.

Biomarker Potential

MBP has also been identified as a potential biomarker for MS. The diagnosis of MS is often based on the presence of certain symptoms, such as muscle weakness, stiffness, and fatigue. These symptoms are difficult to measure, and there is a need for more biomarkers to improve the accuracy of the diagnosis. MBP is a potential biomarker for MS because its levels can be easily measured and because it is thought to be involved in the development and progression of the disease.

MBP has been shown to be abnormally expressed in the brains of people with MS, and it has been suggested as a potential biomarker for the disease. Further research is needed to confirm its utility as a biomarker for MS and to determine its potential as a drug target.

Conclusion

MBP is a promising drug target and biomarker for the treatment of MS. Its high expression level in the brain and its involvement in the regulation of pain perception, inflammation, and neuropathic pain make it an attractive target for drugs that can modulate its levels or its function. Further research is needed to confirm its utility as a drug target and biomarker for MS.

Protein Name: Myelin Basic Protein

Functions: The classic group of MBP isoforms (isoform 4-isoform 14) are with PLP the most abundant protein components of the myelin membrane in the CNS. They have a role in both its formation and stabilization. The smaller isoforms might have an important role in remyelination of denuded axons in multiple sclerosis. The non-classic group of MBP isoforms (isoform 1-isoform 3/Golli-MBPs) may preferentially have a role in the early developing brain long before myelination, maybe as components of transcriptional complexes, and may also be involved in signaling pathways in T-cells and neural cells. Differential splicing events combined with optional post-translational modifications give a wide spectrum of isomers, with each of them potentially having a specialized function. Induces T-cell proliferation

The "MBP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MBP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MBTD1 | MBTPS1 | MBTPS2 | MC1R | MC2R | MC3R | MC4R | MC5R | MCAM | MCAT | MCC | MCCC1 | MCCC2 | MCCD1 | MCCD1P1 | MCEE | MCEMP1 | MCF2 | MCF2L | MCF2L-AS1 | MCF2L2 | MCFD2 | MCFD2P1 | MCHR1 | MCHR2 | MCHR2-AS1 | MCIDAS | MCL1 | MCM10 | MCM2 | MCM3 | MCM3AP | MCM3AP-AS1 | MCM4 | MCM5 | MCM6 | MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18